Abstract: The present application discloses systems and methods for determining one or more configuration settings for a first hearing prosthesis based on configuration data associated with a second hearing prosthesis. In some embodiments, determining the one or more configuration settings for the first hearing prosthesis may include determining an acoustic operating range associated with the first hearing prosthesis based on whether a configured gain at one or more frequencies for the second hearing prosthesis meets or exceeds a target gain at the one or more frequencies. Some embodiments may also include storing the determined configuration settings in a tangible computer readable memory associated with the first hearing prosthesis.

Abstract: The invention provides a method of treating a tumor or other lesion comprising introducing a solution comprising one or more radioactive isotopes directly into said tumor or other lesion in a mammal to effect in situ precipitation of a radioactive precipitate in the tumor or other lesion.

Abstract: The invention provides a method of treating a tumor or other lesion comprising introducing a solution comprising one or more radioactive isotopes directly into said tumour or other lesion in a mammal to effect in situ precipitation of a radioactive precipitate in the tumour or other lesion.

Abstract: The invention is concerned with Nuclear Magnetic Resonance (NMR) spectroscopy and Magnetic Resonance Imaging (MRI), particularly NMR spectroscopy. It provides hyperpolarization methods offering enhanced sensitivity of detection over conventional NMR for studying the fate of a test compound in a biological system. The methods are particularly suitable for studying metabolism and toxicity of drugs. The resulting NMR sensitivity increase is advantageous in two key aspects of NMR detection: test compounds can be detected at lower concentrations and substantial time saving can be achieved in cases where extensive averaging is conventionally employed to increase the signal to noise ratio of the corresponding NMR spectra. The methods can be used for studios that were not practical or not possible using conventional NMR.

Abstract: A fluid sampling element is adapted to receive a fluid sample, but also includes a pH sensor element adapted to measure pH of the fluid sample and a reference sensor element. The pH sensor element and the reference sensor element are adapted to generate a potential difference between each other based on the pH of the fluid sample. The pH of the fluid sample can be measured and the fluid sampling element can then be readily disposed of.

Abstract: An in vitro assay method which comprises the use of an assay reagent containing at least one NMR active nucleus, and hyperpolarising at least one NMR active nucleus of the assay reagent; and analysing the assay reagent and/or the assay by NMR spectroscopy and/or NMR imaging. The assay reagent may contain an artificially high concentration of an NMR active nucleus.

Abstract: This invention concerns drug delivery by way of mesh sleeves for use with devices adapted for insertion into the vagina, rectum, nasal or buccal cavity. The resulting apparatus exploit the highly vascularised nature of the tissue of bodily cavities such as the vagina, nose, rectum and mouth to deliver pharmaceutical agents to localised areas and/or into underlying tissues.

Abstract: Synthetic analogues of lysine and glutamine are provided which function as substrates for the fibrin-stabilising enzyme Factor XIIIa even when labelled with a detectable moiety. The use of suitable protecting groups provides compounds which possess reduced susceptibility to in vivo metabolism especially by peptidases, and are hence useful agents for the diagnosis of thrombosis, embolism, atherosclerosis, inflammation or cancer.

Abstract: This invention relates to compounds of formula (I) and (II) that are useful in treating vascular endothelial growth factor (VEGF)-mediated disorders, particularly endometriosis and acute macular degenerative disorder. The invention also relates to a topical system for the treatment of acute macular degenerative disorder comprising a VEGF inhibitor.

Abstract: Synthetic analogues of lysine and glutamine are provided which function as substrates for the fibrin-stabilising enzyme Factor XIIIa even when labelled with a detectable moiety. The use of suitable protecting groups provides compounds which possess reduced susceptibility to in vivo metabolism especially by peptidases, and are hence useful agents for the diagnosis of thrombosis, embolism, atherosclerosis, inflammation or cancer.

Abstract: A complex of a radiometal or paramagnetic metal ion with a metal chelating agent such as a diaminedioxime has attached thereto a substituent of formula (Y)m-A-NHR)k can function as a substrate for the fibrin-stabilizing Factor XIIIa. The complex is useful for the diagnosis or therapy of thrombosis, embolism, atherosclerosis, inflammation or cancer.

Abstract: The invention relates to a method for the treatment of an oestrogen-dependent proliferative disorder of the uterus such as endometriosis and uterine fibroids in a patient, by administering an aromatase inhibitor to the patient intravaginally. This achieves high local levels of aromatase inhibitor Locally, and therefore avoids some of the adverse reactions that are observed when aromatase inhibitors are delivered orally. Further, intravaginal delivery allows inhibition of the local lesional production without significantly affecting the circulating levels which have been produced by the ovaries. This results in minimal side-effects and will allow for longer term treatment than current therapies.

Abstract: The invention relates to a method for the treatment of vulvar vestibulitis, by the topical application to an affected tissue of a therapeutically-effective amount of an agent that prevents or reduces the activation of T-lymphocyte cells, such as tacrolimus, everolimus, sirolimus or cyclosporin.

Abstract: The invention relates to drug delivery devices for insertion into the vagina, rectum or nasal cavity comprising a body, a layer of fluid-impermeable material on at least part of said body and one or more pharmaceutical agents disposed on the surface of the material remote from said body, wherein said body comprises absorbent material. The devices exploit the highly vascularised nature of the vaginal, nasal and rectal mucosal tissue to deliver pharmaceutical agents to localised areas and/or into underlying tissues.

Abstract: A complex of a radiometal or paramagnetic metal ion with a metal chelating agent such as a diaminedioxime has attached thereto a substituent of formula (Y)m—A—NHR)k can function as a substrate for the fibrin-stabilizing Factor XIIIa. The complex is useful for the diagnosis or therapy of thrombosis, embolism, atherosclerosis, inflammation or cancer.

Abstract: The invention is concerned with Nuclear Magnetic Resonance (NMR) spectroscopy and Magnetic Resonance Imaging (MRI), particularly NMR spectroscopy. It provides hyperpolarisation methods offering enhanced sensitivity of detection over conventional NMR for studying the fate of a test compound in a biological system. The methods are particularly suitable for studying metabolism and toxicity of drugs. The resulting NMR sensitivity increase is advantageous in two key aspects of NMR detection: test compounds can be detected at lower concentrations and substantial time saving can be achieved in cases where extensive averaging is conventionaly employed to increase the signal to noise ratio of the corresponding NMR spectra. The methods can be used for studios that were not practical or not possible using conventional NMR.

Abstract: A complex of a radiometal or paramagnetic metal ion with a metal chelating agent such as a diaminedioxime has attached thereto a substituent of formula —(Y)m—A—NHR, can function as a substrate for the fibrin-stabilizing Factor XIIIa. The complex is useful for the diagnosis or therapy of thrombosis, embolism, atherosclerosis, inflammation or cancer.

Abstract: A human leucocyte elastase (HLE) inhibitor labelled with a detector moiety where the inhibitor is synthetic and has a molecular weight of less than 2000, is useful for the diagnostic imaging of sites of inflammation of infection in vivo, for labelling leucocytes in vitro, or for radiotherapy of rthritis. The HLE inhibitor is preferably a &bgr;-lactam or an azetidinone.

Abstract: The invention relates to drug delivery devices for insertion into the vagina, rectum or nasal cavity comprising a body, a layer of fluid-impermeable material on at least part of said body and one or more pharmaceutical agents disposed on the surface of the material remote from said body, wherein said body comprises absorbent material. The devices exploit the highly vascularised nature of the vaginal, nasal and rectal mucosal tissue to deliver pharmaceutical agents to localised areas and/or into underlying tissues.